Ally Bridge Group leads $150m Covid-19 life science funding

21 May 2020 (Last Updated May 21st, 2020 15:54)

Life science investment firm Ally Bridge Group (ABG) has led three US medtech investments amid the Covid-19 pandemic.

Each of the three companies could have a role to play as the pandemic continues.

ABG has led a $25m investment in Vida Health, an all-in-one virtual care platform managing polychronic physical and behavioural conditions such as diabetes, obesity, hypertension and mental health conditions.

The investment group has also led a $60m investment in Rapid Micro Biosystems, a life science tools company that offers products for the detection and data-tracking of bacterial contamination in the manufacturing of pharmaceuticals, biologics, medical devices, water and food processing, and personal care products.

Finally, it has led an investment of a further $66m in Pulmonx, a medical device company specialising in minimally invasive treatment for patients with severe emphysema.

ABG founder and CEO Frank Yu said: “The Covid-19 pandemic is undoubtedly a watershed event for life science and healthcare around the globe, and further strengthens ABG's commitment to leading high-impact investments in game-changing innovations in this space.”